Drug Delivery Solutions
NanoOncology
NanoOncology

Evirna Program

NanoOncology™ has invented EVIRNA™ a small interfering RNA (siRNA) designed to down-regulate expression of EVI1 in cancer cells. EVIRNA™ recognizes, via sequence complementarity, a portion of the mRNA expressed from the third exon of the EVI1 gene. Inhibition of the expression of EVI1 within a cancer cell causes a block of the cell's division and/or an activation of apoptosis. EVIRNA™ is a 21-nt duplex designed to bind to appropriate intracellular machinery (see "SIRNA TECHNOLOGY" page) factor and interact with EVI1 mRNA. The RISC-siRNA-mRNA complex formation triggers cleavage of EVI1 mRNA, thereby preventing its translation into protein. In order to prevent EVIRNA™ degradation by nucleases and enhance its uptake by tumor cells in vivo, NANO can formulate EVIRNA™ within polypeptide-based hELP™ nanoparticles (see"hELP™" page)